STOCK TITAN

Bioceres (NASDAQ: BIOX) faces Nasdaq warning over sub-$1.00 bid price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Bioceres Crop Solutions Corp. reported that it received a Nasdaq bid-price deficiency notice after its ordinary shares closed below $1.00 for 30 consecutive business days, breaching Nasdaq Listing Rule 5450(a)(1). The notice does not immediately affect the Nasdaq Global Select Market listing, and the BIOX shares continue to trade.

Bioceres has 180 calendar days, until September 14, 2026, to regain compliance by having a closing bid price at or above $1.00 for at least ten consecutive business days. If it fails to do so, the company may seek an additional 180-day period but could ultimately face delisting if it cannot meet Nasdaq’s requirements. Management states it is committed to regaining compliance and will monitor the share price and consider available options.

Positive

  • None.

Negative

  • None.

Insights

Nasdaq bid-price deficiency raises listing-risk over the next compliance periods.

Bioceres Crop Solutions has fallen below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a formal deficiency notice under Rule 5450(a)(1). The shares remain on the Nasdaq Global Select Market, so this is a regulatory warning rather than an immediate trading halt.

The company now has 180 calendar days, until September 14, 2026, to lift its closing bid to at least $1.00 for ten consecutive business days. If it fails, it may apply for an additional 180-day grace period, subject to meeting other Nasdaq initial listing standards, including market value of publicly held shares.

Should Bioceres be unable to demonstrate a credible plan or eligibility to cure, Nasdaq staff may initiate delisting. Management indicates it is committed to regaining compliance and will monitor the share price and consider options, but the specific tools or actions are not detailed in this disclosure.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rules 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of March 2026

 

Commission File Number: 001-38836

 

BIOCERES CROP SOLUTIONS CORP.

(Translation of registrant’s name into English)

 

Ocampo 210 bis, Predio CCT, Rosario

Province of Santa Fe, Argentina

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F  x                                                                 Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ 

 

 

 

 

 

 

Exhibit List

 

Exhibit No.     Description  
99.1   Press Release of Bioceres Crop Solutions Corp. dated March 16, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOCERES CROP SOLUTIONS CORP.
  (Registrant)
     
Dated: March 17, 2026 By: /s/ Federico Trucco
  Name: Federico Trucco
  Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

Receival of Nasdaq Bid Price Letter

 

ROSARIO, Argentina – March 16, 2026 - Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (the “Company”), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, today announced that it received today a letter (the “Nasdaq Bid Price Letter”) from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1).

 

The Nasdaq Bid Price Letter has no immediate effect on the listing of the Company’s ordinary shares, and its ordinary shares will continue to trade on The Nasdaq Global Select Market under the symbol “BIOX”.

 

Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until September 14, 2026, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance with Rule 5450(a)(1) will be regained.

 

In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Global Select Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the NASDAQ staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by NASDAQ. The Company is committed to regaining compliance.

 

The Company intends to actively monitor the closing bid price for its ordinary shares and will consider available options to resolve the deficiency and regain compliance with Rule 5450(a)(1).

 

About Bioceres Crop Solutions Corp.

 

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4 program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit investors.biocerescrops.com.

 

Forward Looking Statements

 

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including factors that are described in the sections entitled “Risk Factors” in the Company’s Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

 

Bioceres Crop Solutions Corp.

Paula Savanti

Head of Investor Relations

investorrelations@biocerescrops.com

 

 

 

FAQ

What did Bioceres Crop Solutions Corp. (BIOX) disclose in this Form 6-K?

Bioceres disclosed it received a Nasdaq bid-price deficiency notice because its ordinary shares closed below $1.00 for 30 consecutive business days. The company explained the compliance timeline, potential consequences, and stated it is committed to regaining compliance while its shares continue trading on the Nasdaq Global Select Market.

Why did Nasdaq send Bioceres (BIOX) a minimum bid price notice?

Nasdaq sent the notice because the closing bid price of Bioceres’ ordinary shares stayed below the required $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). This breach triggers a formal deficiency process, although it does not immediately suspend or delist the stock from trading.

How long does Bioceres (BIOX) have to regain Nasdaq bid-price compliance?

Bioceres has an initial 180-day period, until September 14, 2026, to regain compliance by achieving a closing bid of at least $1.00 for ten consecutive business days. If it does not regain compliance, it may qualify for a further 180 days, subject to other Nasdaq listing standards.

Can Bioceres (BIOX) be delisted from Nasdaq because of this bid-price issue?

Yes, delisting is a potential outcome if Bioceres cannot cure the deficiency. After the 180-day compliance period, and any possible additional 180-day extension, Nasdaq staff may move toward delisting if the company neither regains a $1.00 bid price nor meets eligibility for continued listing.

What actions does Bioceres (BIOX) plan regarding the Nasdaq deficiency notice?

Bioceres states it is committed to regaining compliance with Nasdaq’s bid-price rule. The company intends to closely monitor the closing bid price of its ordinary shares and consider available options to resolve the deficiency, though this disclosure does not specify particular measures or corporate actions.

Does the Nasdaq deficiency notice affect current trading of Bioceres (BIOX) shares?

The notice has no immediate effect on trading. Bioceres’ ordinary shares continue to trade on the Nasdaq Global Select Market under the symbol BIOX. The deficiency notice instead starts a compliance period during which the company must restore its bid price to Nasdaq’s required minimum.

Filing Exhibits & Attachments

1 document
Bioceres Crop Solutions Corp

NASDAQ:BIOX

View BIOX Stock Overview

BIOX Rankings

BIOX Latest News

BIOX Latest SEC Filings

BIOX Stock Data

27.64M
47.27M
Agricultural Inputs
Basic Materials
Link
Argentina
Rosario